Eden Innovations Reports $1.98 Million Revenue and $6.78 Million Loss

Debt Eliminated, But Losses Continue

Eden Innovations Ltd (ASX:EDE) has completed one of the more dramatic balance-sheet repairs seen in its recent history, but the annual report makes clear that financial survival has not yet become commercial self-sufficiency.

Interest-bearing liabilities fell from $16.97 million at 30 June 2025 to $1.23 million a year later, before the remaining related-party loans and accrued directors’ fees were settled through the issue of 20.7 million shares in August 2026. Eden now says it has negligible interest-bearing debt. Cash and term deposits stood at $5.41 million at year-end, while net assets swung from a deficiency of $1.94 million to $14.02 million.

The repair came through a combination of equity raisings, debt-for-equity conversions and the sale of Eden’s Augusta, Georgia property for US$5 million. That sale generated a $4.25 million accounting gain and helped repay the high-cost iBorrow facility secured over the Group’s US properties. The balance-sheet improvement is substantial, although much of it was achieved by issuing shares rather than by generating cash from operations.

Revenue Falls as Product Mix Changes

Group revenue fell to $1.98 million from $2.43 million, with the $6.78 million statutory loss only modestly below the prior year’s $7.12 million loss. The result also included a $5.19 million non-cash loss on extinguishing loans through the issue of shares and options, meaning the headline loss does not provide a clean view of underlying trading performance.

EdenCrete revenue fell 42% to $786,903. Management attributed the decline to the timing of bulk purchases by major customers, rather than a reduction in the number of plants equipped to use EdenCrete Pz7. That installed base rose from 16 plants at the start of the year to 29 at year-end, with Amrize expanding installations across the US and Canada and Holcim Ecuador remaining Eden’s largest single EdenCrete customer.

OptiBlend provided the brighter revenue line. Total sales and services rose 10% to $1.19 million, representing 60% of Group revenue compared with 44% a year earlier. US revenue increased 16% in US dollar terms, supported by new demand from data-centre operators seeking longer back-up generator run times, although the reported figure included a US$156,000 refund relating to an order that could not proceed because of a customer ordering error.

Trials Advance, Commercial Conversion Still Pending

The company’s commercial narrative rests heavily on EdenCrete Pz7’s expanding trial and installation footprint. Final results from India’s Central Road Research Institute confirmed, in the trial mixes described by Eden, compressive-strength gains of up to 19%, flexural-strength gains of up to 14%, abrasion-loss reductions of up to 28% and drying-shrinkage reductions of up to 25% against control mixes. The results also pointed to a role for fly ash in improving the benefit of the carbon nanotube admixture and reducing cement consumption.

Those findings sit alongside further Pz7 installations and requested installations in Colorado, Texas, Minnesota and the Greater Toronto area. The company has also launched EdenShield, bringing together its concrete, dual-fuel and carbon-nanotube technologies for defence and critical-infrastructure applications. These are potentially important avenues, but the report describes EdenShield as being at an early stage and does not report material revenue from the new division.

Auditor Flags Funding Uncertainty

Despite the unmodified audit opinion, Stantons International Audit and Consulting drew attention to a material uncertainty related to going concern. Eden used $4.49 million in operating cash during FY2026, up from $3.70 million the year before, and remains dependent on sales growth, cost reductions and continued access to capital.

The board has begun a cost review across its Australian, US and Indian operations, citing a desire to reduce the underlying operating cash outflow and bring forward cash-flow break-even. The June 2026 quarter recorded net operating cash outflow of $1.90 million, although Eden said roughly $800,000 comprised one-off, annual and timing items. The distinction will matter only if subsequent quarters show a sustained reduction in cash burn.

There is also a substantial equity overhang. At 19 September 2026, Eden had 631.9 million ordinary shares on issue, alongside 136.9 million quoted options and a large number of unquoted options and performance rights. The balance sheet may now be lighter, but future funding and incentive arrangements can still expand the share count.